Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

被引：5
|
作者：
Hussain, Syed A.
Maroto, Pablo
Climent, Miguel Angel
Bianchini, Diletta
Jones, Robert Hugh
Lin, Chia-Chi
Wang, Shian-Shiang
Dean, Emma
Crossley, Kate
Schlieker, Laura
Bogenrieder, Thomas
De Bono, Johann S.
机构：
[1] Univ Sheffield, Acad Unit Oncol, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Inst Canc Res, London, England
[5] Royal Marsden, London, England
[6] Velindre Canc Ctr, Cardiff, S Glam, Wales
[7] Cardiff Univ, Cardiff, S Glam, Wales
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[12] Boehringer Ingelheim Pharma Gmbh & Co KG, Staburo Gmbh & Co KG, Munich, Germany
[13] Boehringer Ingelheim RCV, Vienna, Austria
[14] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [3] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
    Chi, K. N.
    Taavitsainen, S.
    Iqbal, N.
    Ferrario, C.
    Ong, M.
    Wadhwa, D.
    Hotte, S. J.
    Lo, G.
    Tran, B.
    Azad, A.
    Wood, L.
    Gingerich, J. R.
    North, S.
    Pezaro, C. V.
    Ruether, D.
    Sridhar, S. S.
    Annala, M.
    Bacon, J.
    Wyatt, A. W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [6] Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).
    Liu, Zhenhua
    Wei, Qiang
    Feng, Ping
    Jiang, Shusuan
    Luo, Hong
    Liao, Hong
    Yu, Dexin
    Chen, Zhiwen
    Zhang, Dahong
    Dai, Tao
    Li, Zeng
    Zhang, Zhiqiang
    Bai, Hong
    Liu, Feng
    Wang, Wenliang
    Lin, Jiaqin
    Wang, Yike
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.
    Climent, Miguel Angel
    Sanchez, Alfredo
    Mellado, Begona
    Santander, Carmen
    Cassinello, Javier
    Isabel Saez, M.
    Lazaro Quintela, Martin
    Maroto Rey, Jose Pablo
    Mendez-Vidal, Maria Jose
    del Alba, Aranzazu Gonzalez
    Grande, Enrique
    Duran, Ignacio
    Esteban, Emilio
    Font, Albert
    Arranz Arjia, Jose Angel
    Puente, Javier
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
    Morris, Michael J.
    Heller, Glenn
    Hillman, David W.
    Bobek, Olivia
    Ryan, Charles
    Antonarakis, Emmanuel S.
    Bryce, Alan H.
    Hahn, Olwen
    Beltran, Himisha
    Armstrong, Andrew J.
    Schwartz, Lawrence
    Lewis, Lionel D.
    Beumer, Jan H.
    Langevin, Brooke
    McGary, Eric C.
    Mehan, Paul T.
    Goldkorn, Amir
    Roth, Bruce J.
    Xiao, Han
    Watt, Colleen
    Taplin, Mary-Ellen
    Halabi, Susan
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3352 - +
12345